GSK’s Jemperli has claimed an edge over its main rival in the endometrial cancer therapy market after showing improved overall survival in a broad patient population in the RUBY trial.
L'Aifa, Agenzia Italiana del Farmaco, ha approvato 13 nuovi farmaci per il rimborso. Durante la prima riunione del 2025, il ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback